Panacea Biotec Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Under the revision, the contract value for 2026 has been increased by $2.55 million (around Rs 23 crore) to $16.8 million, while the 2027 allocation rises by $2.70 million (around Rs 24 crore) to $15.18 million. Additionally, an extra award for 2027 worth $3.68 million (about Rs 33 crore) has been included, taking the total incremental value to $8.93 million (roughly Rs 80 crore) for the two years.

The international supply contract will be executed as per orders received from UNICEF during CY2026 and CY2027. UNICEF is expected to publish details of the award, including supplier name, vaccine, duration, total value, and awarded prices per product on its official website.

Panacea Biotec said the award does not involve any promoter or promoter group interest.

Panacea Biotec is a research-based biotechnology companies engaged in the business of research, development, manufacture, and marketing of vaccines in India and international markets.

The company reported a consolidated net loss of Rs 13.92 crore in Q2 FY26 as against a net profit of Rs 4.80 crore in Q2 FY25. Revenue from operations declined 4.2% year on year to Rs 141.13 crore in Q2 FY25.

Powered by Capital Market - Live News

Vinod Goel (aged ~60 years) is a fellow member of the Institute of Company Secretaries of India and an associate member of the Institute of Cost Accountants of India. He holds B. Com (Hons.), M. Com, and LL. B degrees and has over 35 years of post-qualification experience in corporate governance, finance, legal, M&A, and corporate restructuring. He has been associated with Panacea Biotec since 1999 and currently serves as Group CFO and Head of Legal & Company Secretary.

Panacea Biotec is a research-based biotechnology companies engaged in the business of research, development, manufacture, and marketing of vaccines in India and international markets.

The company reported a consolidated net loss of Rs 13.92 crore in Q2 FY26 as against a net profit of Rs 4.80 crore in Q2 FY25. Revenue from operations declined 4.2% year on year to Rs 141.13 crore in Q2 FY25.

Shares of Panacea Biotec shed 0.67% to Rs 354.95 on the BSE.

Powered by Capital Market - Live News

Net loss of Panacea Biotec reported to Rs 13.92 crore in the quarter ended September 2025 as against net profit of Rs 4.80 crore during the previous quarter ended September 2024. Sales declined 4.22% to Rs 141.13 crore in the quarter ended September 2025 as against Rs 147.35 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

Easyfive TT provides active immunization against severe diseases namely Diphtheria, Haemophilus influenzae type b, Hepatitis-B, Pertussis, and Tetanus.

The company will supply Easyfive TT vaccine during calendar year 2026 and 2027.

Panacea Biotec is a research-based biotechnology companies engaged in the business of research, development, manufacture and marketing of vaccines in India and international markets.

The company reported consolidated net profit of Rs 4.05 crore in Q1 FY26 as against net loss of Rs 15.80 crore in Q1 FY25. Revenue from operations jumped 44.1% year on year to Rs 166.70 crore in Q1 FY26.

The counter declined 2.24% to end at Rs 396.40 on Tuesday, 11 November 2025.

Powered by Capital Market - Live News